Treatment of the cancer anorexia-cachexia syndrome: A critical reappraisal

Journal of Chemotherapy

Volumn 15, Issue 3, 2003, Pages 220-225

  Lelli, Giorgio ^a   Montanari, M ^a   Gilli, G ^a   Scapoli, D ^a   Antonietti, C ^a  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Advanced cancer; Anorexia; Cachexia; Drug therapy; Medroxyprogesterone acetate; Megestrol acetate; Metoclopramide

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANABOLIC AGENT; CANNABINOID; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DEXAMETHASONE; DRONABINOL; FLUOXYMESTERONE; GESTAGEN; HYDRAZINE; INTERLEUKIN 1; INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MELATONIN; METOCLOPRAMIDE; NANDROLONE DECANOATE; OPIATE; PROKINETIC AGENT; THALIDOMIDE; TUMOR NECROSIS FACTOR;

ANOREXIA; APPETITE; ARTIFICIAL FEEDING; CACHEXIA; CANCER; CANCER ANOREXIA CACHEXIA SYNDROME; CANCER PAIN; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG TOXICITY; ENDOCRINE DISEASE; HUMAN; LIVER INJURY; SHORT SURVEY; SYMPTOM; TUMOR CELL; WASTING SYNDROME; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0038684081     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.3.220     Document Type: Short Survey

References (60)

1. Theologides A. The anorexia-cachexia syndrome. A new hyphothesis. Ann NY Acad Sci 1974; 230: 427-34.
2. Waterhouse C. How tumors affect host metabolism. Ann NY Acad Sci 1974, 230: 89-93.
3. DeWys WD, Begg C, Lavin PT et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980; 69: 491-4.
4. Jaskoviak NT, Alexander RH. The pathophysiology of cancer cachexia. In: Doyle D., Hanks GVC, MacDonald N eds. Oxford Textbook of Palliative Medicine. 2nd Edition. Oxford: Oxford Medical Publications, 1998; 534-48.
5. Nelson KA, Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome. J Clin Oncol 1994; 12(1): 213-25.
6. Tisdale MJ. Metabolic abnormalities in cachexia and anorexia. Nutrition 2000, 16(10): 1013-4.
7. Ciechanover A, Schwartz AL. Ubiquitin-mediated degradation of cellular proteins in health and in disease. Hepatology Jan 2002.
8. Giacosa A, Frascio F, Sukkar SG et al. Food intake and body composition in cancer cachexia. Nutrition 1996; 12: S20-S23.
9. Argiles JP, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev 1999; 19(3): 223-48.
10. Simons JP, Schols AM, Buurrman WA, et al. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond) 1999; 97(2): 215-23.
11. Mantovani G, Macciò A, Madeddu C, et al. Role of proinflammatory cytokines and leptin in cancer-related anorexia/cachexia. Metabolic abnormalities and therapeutic approaches. RINPE 2002; 20(1): 13-20.
12. Laviano A, Muscaritoli M, Gianni C, et al. Neurochemical basis of cancer anorexia. RINPE 2002; 20(1): 21-8.
13. Loprinzi CL. Should cancer patients with incurable disease receive parenteral or enteral nutritional support? (Bridging Editorial). Eur J Cancer 1998; 34(3): 279-85.
14. Mercadante S. Parenteral versus enteral nutrition in cancer patients: indications and practice. Supp Care Cancer 1998; 6: 85-93.
15. Schneider S, Blanc-Vincent MP, Nitenberg G, et al. Standards, options and recommendations for home parenteral or enteral nutrition in adult cancer patients. Bull Cancer 2001; 88: 605-18.
16. Tanneberger S, Malavasi I, Mariano P, et al. Planning palliative or terminal care: the dilemma of doctors' prognoses in terminally ill cancer patients. Ann Oncol 2002; 13(8): 1320-2.
17. Kardinal C, Loprinzi CL, Schaid DJ et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990; 65: 2657-62.
18. Gralla RJ, Itri LM, Pisko SE et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazin in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981; 305: 905-9.
19. Bruera E, Belzile M, Neumann C, et al. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Management 2000; 19(6): 427-35.
20. Kochakian CD. II Metabolic effects. In: Kochakian CD ed. Anabolic Steroids. Berlin, Springer Verlag, 1976; 5-72.
21. Chlebowski RT, Herrld J, Ali I, et al. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 1986; 58(1): 183-6.
22. Mantovani G, Macciò A, Massa E, Madeddu C. Managing cancer-related anorexia/cachexia. Drugs 2001; 61(4): 499-514.
23. Moertel C, Schutt AG, Reiteneier RJ, et al. Corticosteroid therapy of pre-terminal gastrointestinal cancer. Cancer 1974; 33: 1607-9.
24. Willox J, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer. BMJ 1984; 200-27.
25. Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69 (718): 751-4.
26. Robustelli Della Cuna C, Pellegrini A, Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in pre-terminal cancer patients: a placebo controlled multicenter study. Eur J Cancer Clin Oncol 1989; 25: 1823-9.
27. Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol 1989; 25: 1823-9.
28. Bruera E, Roca E, Cedaro L et al. Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep 1983; 67(4): 381-3.
29. Watanabe S, Bruera E. Corticosteroids as adjuvant analgesics. J Pain Symptom manage 1994; 9(7): 442-5.
30. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20(2): 567-73.
31. Loprinzi CL, Juross SA, O'Fallon JR, et al. Randomized, placebo-controlled evaluation on hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994; 12: 1121-5.
32. Loprinzi CL, Goldberg RM, Su JQ. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994; 12: 1126-9.
33. Kosty MP, Fleishman SB, Herndon JE, et al. Cisplatin, vinblastine and hydrazine sulfate in advanced non-small-cell lung cancer; a randomized placebo-controlled, double blind phase III study of the cancer and leukemia group B. J Clin Oncol 1994; 12: 1113-20.
34. Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996; 32A(8): 1340-3.
35. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide. Drugs 2000; 60(2): 273-92.
36. Agteresch HJ, Rietveld T, Kerkhofs LGM, et al. Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol 2002; 20(2): 371-8.
37. Gelin J, Moldawer LL, Lonnroth C, et al. Role of endogenous tumor necrosis factor a and interleukin-1 for experimetal tumor growth and the developement of cancer cachexia. Cancer Res 1991; 51: 415-21.
38. Pannuti F, Martoni A, Camaggi CM et al. High dose medroxyprogesterone acetate in oncology. History, clinical use and pharmacokinetics In: F. Cavalli, W.L. McGuire, F. Pannuti, A. Pellegrini, G. Robustelli della Cuna Eds. Proceedings of the Intern. Symp. on Medroxyprogesterone acetate. Amsterdam, Excerpta Medica, 1982; 5-43.
39. Lelli G, Angelelli B, Giambiasi ME et al. The anabolic effect of high dose medroxyprogesterone acetate in oncology. Pharmacol Res Commun 1983; 15(6): 561-8.
40. Lelli G, Angelelli B, Zanichelli L et al. The effect of high dose medroxyprogesterone acetate on water and salt metabolism in advanced cancer patients. Chemioterapia 1984; 3(5): 327-9.
41. Downer S, Joel S, Albright A et al. A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 1993; 67 (5): 1102-5.
42. Simons J, Aaronson NK, Vansteenkiste JF et al. Effects of medroxyprogesterone acetate on appetite, weight and quality of life in advanced stage non hormone sensitive cancer: a placebo controlled multicenter study. J Clin Oncol 1996; 14 (4): 1007-84.
43. Loprinzi CL, Schaid DJ, Dose AM et al. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993; 11: 152-4.
44. Simons JP, Schols AM, Hoefnagels JM, et al. Effects of medroxiprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer. Cancer 1998; 82: 553-60.
45. Tchekmedyian NS, Tait N, Moody M et al. High dose megestrol acetate. A possible treatment for cachexia. JAMA 1987; 257(9): 1195-8.
46. Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 1998; 55(5): 675-88.
47. Gebbia V, Testa A, Gebbia N. Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Br J Cancer 1996; 73: 1576-80.
48. Mantovani G, Macciò A, Lai P et al. Cytokine activity in cancer-related anorexia/cachexia: Role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 1998; 25(2) S6: 45-52.
49. Maltoni M, Nanni O, Scarpi E et al. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome. A systematic review of randomized clinical trials. Ann Oncol 2001; 12: 289-300.
50. Jatoi A, Yamashita J, Sloan JA, et al. Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. Support Care Cancer 2002; 10(1): 71-5.
51. Loprinzi CL, Kugler JW, Sloan JA et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17(10): 3299-306.
52. Bruera E, Sweeney C. Cachexia and astenia in cancer patients. Lancet Oncol 2000; 1: 138-47.
53. Donnelly S, Walsh D. Low-dose megestrol acetate for appetite stimulation in advanced cancer. J Pain Symptom Mngt 1995; 10 (3): 182-3.
54. Loprinzi CL, Michalak JC, Schaid DJ et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993; 11: 762-7.
55. Kurzrock R. The role of cytochines in cancer-related fatigue. Cancer 2001; 92: 1684-8.
56. Lundholm K, Gelin J, Hyltander A et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994; 54: 5602-6.
57. Hussey HJ, Tisdale MJ. Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model. Int J Cancer 2000; 87(1): 95-100.
58. Purasiri P, Murray A, Richardson S, et al. Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer. Clin Sci 1994; 87: 711-7.
59. Wigmore SJ, Ross JA, Falconer JS, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996; 12 Suppl 1: S27-30.
60. Wigmore SJ, Fearon KC, Maingay JP, et al. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci 1997; 92: 215-21.